Verapamil shows potential for preserving beta-cell function in type 1 diabetes
Educatie
European Association for the Study of Diabetes Sep 18 2025 New research (the Ver-A-T1D trial) presented at this year's Annual Meeting of the European Association for the Study of Diabetes (EASD) (Vienna, 15-19 September) shows that slow-release (SR) verapamil (360mg daily) could have a potential effect on beta-cell function in adults with newly diagnosed type 1 diabetes. The study is led by Professor Thomas R. Pieber, Medical University of Graz, Austria, on behalf of the Ver-A-T1D Study Group.
din zilele anterioare